Growing clinically relevant quantities of heart muscle to cure chronic disease
Published on: 23 April 2024
Gray Group
Mammalian Cell Lines and Stem Cell Bioprocesses
The Gray Group is developing novel methods to reduce the cost of producing monoclonal antibodies for therapeutics, and significantly boost the production yields of stem cells for use in regenerative medicines.
The team hopes to initially use stem cells for treating injured heart muscle with a differentiated progeny as cardiomyocytes. Another application area being investigated is their use as neural progenitor cells, which have been difficult to produce, but there are hopes that the thermo-responsive polymer method developed by the Gray and Monteiro Groups could resolve this challenge.
